This underscores a CDMO strategy: leveraging a broad manufacturing network (mammalian, bacterial, sterile filling) to serve glp-1 and other high-growth biologics
What the label actually says The Mounjaro and Zepbound prescribing information states: "Available data with tirzepatide use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes." The label then references animal studies: "Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy." And the recommendation: "Advise pregnant women of the potential risk to a fetus
She has been a registered nurse since 2016 with a diverse background in the operating room and aesthetics/integrative medicine
The company's FAQ states that "PT-141 is FDA-approved for low sexual desire." This requires clarification: bremelanotide (marketed under the brand name Vyleesi) received FDA approval specifically as a subcutaneous injection for hypoactive sexual desire disorder (HSDD) in premenopausal women
Danesh-Meyer said the benefits of the medications remain significant
Using RNA sequencing of bone biopsies from patients treated with denosumab compared with placebo, the authors observed a down-regulation of skeletal DPP-4 expression with denosumab [3]